- Home
- ENSC vs QNTM Comparison
ENSC vs QNTM Comparison
Compare ENSC & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- QNTM
- Stock Information
- Founded
- ENSC 2003
- QNTM 1998
- Country
- ENSC United States
- QNTM Canada
- Employees
- ENSC N/A
- QNTM N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- QNTM
- Sector
- ENSC Health Care
- QNTM
- Exchange
- ENSC Nasdaq
- QNTM NYSE
- Market Cap
- ENSC 7.9M
- QNTM 9.1M
- IPO Year
- ENSC N/A
- QNTM N/A
- Fundamental
- Price
- ENSC $5.40
- QNTM $6.23
- Analyst Decision
- ENSC
- QNTM
- Analyst Count
- ENSC 0
- QNTM 0
- Target Price
- ENSC N/A
- QNTM N/A
- AVG Volume (30 Days)
- ENSC 26.4K
- QNTM 7.0M
- Earning Date
- ENSC 03-14-2025
- QNTM 03-31-2025
- Dividend Yield
- ENSC N/A
- QNTM N/A
- EPS Growth
- ENSC N/A
- QNTM N/A
- EPS
- ENSC N/A
- QNTM N/A
- Revenue
- ENSC $4,421,404.00
- QNTM N/A
- Revenue This Year
- ENSC $89.78
- QNTM N/A
- Revenue Next Year
- ENSC N/A
- QNTM N/A
- P/E Ratio
- ENSC N/A
- QNTM N/A
- Revenue Growth
- ENSC 40.41
- QNTM N/A
- 52 Week Low
- ENSC $2.12
- QNTM $2.70
- 52 Week High
- ENSC $14.67
- QNTM $70.20
- Technical
- Relative Strength Index (RSI)
- ENSC 35.78
- QNTM 46.46
- Support Level
- ENSC $5.34
- QNTM $10.68
- Resistance Level
- ENSC $6.14
- QNTM $12.44
- Average True Range (ATR)
- ENSC 0.43
- QNTM 2.41
- MACD
- ENSC -0.04
- QNTM -0.42
- Stochastic Oscillator
- ENSC 9.49
- QNTM 21.66
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.